CO6241116A2 - Pirimidil piperazinas utiles como ligandos del receptor d3/d2 - Google Patents

Pirimidil piperazinas utiles como ligandos del receptor d3/d2

Info

Publication number
CO6241116A2
CO6241116A2 CO09126013A CO09126013A CO6241116A2 CO 6241116 A2 CO6241116 A2 CO 6241116A2 CO 09126013 A CO09126013 A CO 09126013A CO 09126013 A CO09126013 A CO 09126013A CO 6241116 A2 CO6241116 A2 CO 6241116A2
Authority
CO
Colombia
Prior art keywords
alkyl group
represents hydrogen
phenyl
hydrogen atom
alkyl
Prior art date
Application number
CO09126013A
Other languages
English (en)
Inventor
Szalai Gisella Bartane
Csongor Eva Againe
Gyorgy Domany
Istvan Gyertyan
Bela Kiss
Judit Laszy
Katalin Saghy
Eva Schmidt
Sandor Farkas
Zsolt Komlodi
Original Assignee
Richter Gedeon Nyrt
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Richter Gedeon Nyrt filed Critical Richter Gedeon Nyrt
Publication of CO6241116A2 publication Critical patent/CO6241116A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48—Two nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B53/00—Asymmetric syntheses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/30—Halogen atoms or nitro radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/09—Geometrical isomers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invención se relaciona con nuevos ligandos de dopamina D3 y D2 de fórmula (I):en donde R1, R2 y Q son como se describe aquí, y/o isómeros geométricos y/o estereoisómeros y/o diastereómeros y/o sales y/o hidratos y/o solvatos y/o polimorfos de los mismos. La invención también se relaciona con procesos para preparar los mismos, con composiciones que contienen los mismos y con su uso en el tratamiento y/o prevención de afecciones que requieren modulación de receptores de dopamina. 1.- Un compuesto de fórmula (I):en donde Q representa grupo alquilo C1-4, -NR3R4, fenilo, fenilo opcionalmente sustituido, 1-pirrolidinilo, 1-piperidinilo, 4-R5-piperazin1-ilo o 4-morfolinilo, R1 representa hidrógeno o grupo alquilo C1-4;R2 representa hidrógeno o grupo alquilo C1-4; R3 representa hidrógeno, grupo alquilo C1-4, fenilo o fenilo opcionalmente sustituido; R4 representa hidrógeno, grupo alquilo C1-4, fenilo o fenilo opcionalmente sustituido; R5 representa hidrógeno o grupo alquilo C1-4; y/o isómeros geométricos y/o estereoisómeros y/o diastereómeros y/o sales y/o hidratos y/o solvatos y/o polimorfos de los mismos. 2.- Un compuesto de la reivindicación 1, en donde Q representa grupo alquilo C1-4, -NR3R4 o 4-morfolinilo, R1 representa átomo de hidrógeno o grupo alquilo C1-4; R2 representa átomo de hidrógeno o grupo alquilo C1-4;R3 representa átomo de hidrógeno o grupo alquilo C1-4; y R4 representa átomo de hidrógeno o grupo alquilo C1-4.
CO09126013A 2007-04-11 2009-11-06 Pirimidil piperazinas utiles como ligandos del receptor d3/d2 CO6241116A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
HU0700269A HUP0700269A2 (en) 2007-04-11 2007-04-11 Pyrimidinyl-piperazines useful as d3/d2 receptor ligands, pharmaceutical compositions containing them and their use

Publications (1)

Publication Number Publication Date
CO6241116A2 true CO6241116A2 (es) 2011-01-20

Family

ID=38336883

Family Applications (1)

Application Number Title Priority Date Filing Date
CO09126013A CO6241116A2 (es) 2007-04-11 2009-11-06 Pirimidil piperazinas utiles como ligandos del receptor d3/d2

Country Status (36)

Country Link
EP (1) EP2132185B1 (es)
JP (1) JP4580464B2 (es)
KR (1) KR101540821B1 (es)
CN (1) CN101652351B (es)
AP (1) AP2460A (es)
AT (1) ATE518843T1 (es)
AU (1) AU2008237696B2 (es)
BR (1) BRPI0809641A2 (es)
CA (1) CA2682817C (es)
CO (1) CO6241116A2 (es)
CR (1) CR11071A (es)
CU (1) CU23853B1 (es)
CY (1) CY1111962T1 (es)
DK (1) DK2132185T3 (es)
EA (1) EA016174B1 (es)
EC (1) ECSP099702A (es)
ES (1) ES2370748T3 (es)
GE (1) GEP20115272B (es)
HK (1) HK1134491A1 (es)
HR (1) HRP20110785T8 (es)
HU (1) HUP0700269A2 (es)
IL (1) IL200801A0 (es)
MA (1) MA31359B1 (es)
MX (1) MX2009010896A (es)
MY (1) MY148384A (es)
NI (1) NI200900179A (es)
NZ (1) NZ579754A (es)
PL (1) PL2132185T3 (es)
PT (1) PT2132185E (es)
RS (1) RS51979B (es)
SI (1) SI2132185T1 (es)
TN (1) TN2009000386A1 (es)
TW (1) TWI445534B (es)
UA (1) UA103748C2 (es)
WO (1) WO2008125891A2 (es)
ZA (1) ZA200906543B (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9091489B2 (en) 2010-05-14 2015-07-28 Paragon Space Development Corporation Radiator systems
NZ605431A (en) 2010-06-18 2015-06-26 Altos Therapeutics Llc D2 antagonists, methods of synthesis and methods of use
US9376396B2 (en) 2012-10-22 2016-06-28 AbbVie Deutschland GmbH & Co. KG Acylaminocycloalkyl compounds suitable for treating disorders that respond to modulation of dopamine D3 receptor
HU229987B1 (en) * 2012-11-21 2015-04-28 Richter Gedeon Nyrt Process for the preparation of pyrimidinyl-piperazines
EP3495363B1 (en) 2016-07-28 2023-08-23 Shionogi & Co., Ltd Nitrogen-containing condensed ring compounds having dopamine d3 receptor antagonistic effect
JPWO2019146739A1 (ja) 2018-01-26 2021-01-07 塩野義製薬株式会社 ドーパミンｄ３受容体拮抗作用を有する縮環化合物
WO2019146740A1 (ja) * 2018-01-26 2019-08-01 塩野義製薬株式会社 ドーパミンｄ３受容体拮抗作用を有する環式化合物
WO2024072930A1 (en) * 2022-09-30 2024-04-04 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Dopamine d3/d2 receptor partial agonists for the treatment of neuropsychiatric disorders

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2311776A1 (fr) * 1975-05-23 1976-12-17 Sogeras Diamino-2,4 bromo-5 chloro-6 pyrimidines et procede pour leur preparation
US4957921A (en) 1989-12-06 1990-09-18 Warner-Lambert Company Substituted cyclohexanols as central nervous system agents
US5047406A (en) 1989-12-06 1991-09-10 Warner-Lambert Co. Substituted cyclohexanols as central nervous system agents
SE9802208D0 (sv) 1998-06-22 1998-06-22 Astra Pharma Inc Novel compounds
US6919342B2 (en) 2003-06-05 2005-07-19 Abbott Gmbh & Co. Kg Triazole compounds suitable for treating disorders that respond to modulation of the dopamine D3 receptor
HU227534B1 (en) 2003-08-04 2011-08-29 Richter Gedeon Nyrt (thio)carbamoyl-cyclohexane derivatives, process for producing them and pharmaceutical compositions containing them
EP1870405A1 (en) * 2006-06-22 2007-12-26 Bioprojet Carbonylated (Aza)cyclohexanes as dopamine D3 receptor ligands

Also Published As

Publication number Publication date
BRPI0809641A2 (pt) 2014-11-11
TN2009000386A1 (en) 2010-12-31
AU2008237696B2 (en) 2013-03-14
CN101652351A (zh) 2010-02-17
EP2132185B1 (en) 2011-08-03
PT2132185E (pt) 2011-11-21
HUP0700269A2 (en) 2009-04-28
NI200900179A (es) 2010-06-30
GEP20115272B (en) 2011-08-25
CN101652351B (zh) 2012-07-04
PL2132185T3 (pl) 2011-12-30
CY1111962T1 (el) 2015-11-04
MY148384A (en) 2013-04-15
EP2132185A2 (en) 2009-12-16
MX2009010896A (es) 2009-12-14
TWI445534B (zh) 2014-07-21
ES2370748T3 (es) 2011-12-22
NZ579754A (en) 2011-11-25
IL200801A0 (en) 2010-05-17
DK2132185T3 (da) 2011-10-03
HRP20110785T8 (en) 2012-04-30
ECSP099702A (es) 2009-11-30
ATE518843T1 (de) 2011-08-15
KR101540821B1 (ko) 2015-07-30
CA2682817A1 (en) 2008-10-23
CU23853B1 (es) 2012-10-15
ZA200906543B (en) 2010-06-30
KR20100082713A (ko) 2010-07-19
EA016174B1 (ru) 2012-02-28
AP2009004970A0 (en) 2009-10-31
HRP20110785T1 (hr) 2011-11-30
JP2010523642A (ja) 2010-07-15
MA31359B1 (fr) 2010-05-03
CA2682817C (en) 2015-11-24
WO2008125891A2 (en) 2008-10-23
HK1134491A1 (en) 2010-04-30
WO2008125891A3 (en) 2009-01-08
TW201002328A (en) 2010-01-16
RS51979B (en) 2012-02-29
CR11071A (es) 2009-11-20
EA200901391A1 (ru) 2010-02-26
SI2132185T1 (sl) 2011-11-30
HU0700269D0 (en) 2007-05-29
AU2008237696A1 (en) 2008-10-23
AP2460A (en) 2012-09-13
UA103748C2 (uk) 2013-11-25
JP4580464B2 (ja) 2010-11-10
CU20090161A7 (es) 2011-09-21

Similar Documents

Publication Publication Date Title
CO6241116A2 (es) Pirimidil piperazinas utiles como ligandos del receptor d3/d2
PE20121048A1 (es) Derivados de imidazolidin-2-ona 1,3-disustituida como inhibidores de cyp17
TW200639158A (en) New compounds with therapeutic effect
AR058546A1 (es) Derivados de 2- adamantilurea como inhibidores selectivos de 11 beta - hsd1
ECSP099388A (es) Derivados de azaadamatano y sus usos como ligandos de los receptores nicoticos de acetilcolina
EA201170096A1 (ru) Замещенные производные пиримидона
PE20110150A1 (es) Amidofenoxiindazoles como inhibidores de c-met
MX2019012336A (es) Compuestos inhibidores del transportador vesicular de monoaminas 2 (vmat2) y composiciones de los mismos.
MY186165A (en) New bicyclic dihydroquinoline-2-one derivatives
AR046085A1 (es) Agonistas etilamino amino sustituidos del receptor beta 2 adrenergico
CO6531418A2 (es) Estabilizante de amina estéricamente inhibida
AR085088A1 (es) Inhibidores de histona desacetilasa y composiciones farmaceuticas que los contienen
ECSP14013296A (es) Derivados de etinilo
AR061973A1 (es) Compuesto de 2-arilindol sustituido en la posicion 5, composicion farmaceutica que lo comprende, compuestos intermedios y procedimiento para la preparacion de los mismos
CR10671A (es) Compuestos azabiciclicos como inhibidores de la recaptacion de monoaminas
CO6531478A2 (es) Derivados de etinilo
PE20240022A1 (es) Derivados de fosforo como nuevos inhibidores de sos1
CO6341560A2 (es) Proceso para la preparacion de derivados de pirimidina sustituidos.
AR079294A1 (es) Acidos homoglutamico y acidos glutamico marcados con yodo y metodo de preparacion de los mismos
EA201390374A1 (ru) Гетероциклические соединения для лечения или профилактики расстройств, вызываемых ослабленной нейротрансмиссией серотонина, норэпинефрина или допамина
AR072880A1 (es) Derivados nitrogenados de la pancratistatina
NI201300011A (es) Formulaciones
CO2017011511A2 (es) Derivados de indol
AR081382A1 (es) Derivados de n-heterocicloalquil bipirrolidinilfenil amida sustituidos, composiciones farmaceuticas que los contienen y uso de los mismos para el tratamiento de enfermedades del sistema nervioso central.
TH139377A (th) ไพริมิดินิล-ไพเพอราซีนซึ่งมีประโยชน์ในการเป็น d3/d2 รีเซพเตอร์ลิแกนด์

Legal Events

Date Code Title Description
FG Application granted